# Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism

> **NCT07328230** · NA · RECRUITING · sponsor: **Chinese Academy of Medical Sciences, Fuwai Hospital** · enrollment: 172 (estimated)

## Conditions studied

- Idiopathic Hyperaldosteronism
- Hyperaldosteronism

## Interventions

- **PROCEDURE:** Superselective Adrenal Arterial Embolization
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT07328230
- **Lead sponsor:** Chinese Academy of Medical Sciences, Fuwai Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328230, "Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07328230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*